Specialize Course

cousres

School of University

School of University

School of University

B-Tech

S. No.

Course

Branch

Duration

Eligibility

Mode

Admission Fees

(Prospectus +Enrollment)

Fees

(Per Sem.)

Exam Fees (Per Sem.)

1

B.Tech

Civil Engg.

4 Years

10+2 with PCME

Semester

2300

15000

1200

2

B.Tech (Lateral Entry 3rd Sem.)

Civil Engg.

3 Years

3 Years Polo technical Diploma/B.Sc in Math

Semester

2300

16000

1200

3

B.Tech

Electrical Engg.

4 Years

10+2 with PCME

Semester

2300

15000

1200

4

B.Tech (Lateral Entry 3rd Sem.)

Electrical Engg.

3 Years

3 Years Polo technical Diploma/B.Sc in Math

Semester

2300

16000

1200

5

B.Tech

Computer Engg.

4 Years

10+2 with PCME

Semester

2300

15000

1200

6

B.Tech (Lateral Entry 3rd Sem.)

Computer Engg.

3 Years

3 Years Polo technical Diploma/B.Sc in Math

Semester

2300

16000

1200

7

B.Tech

Electronics & Telecommunication Engg.

4 Years

10+2 with PCME

Semester

2300

15000

1200

8

B.Tech (Lateral Entry 3rd Sem.)

Electronics & Telecommunication Engg.

3 Years

3 Years Polo technical Diploma/B.Sc in Math

Semester

2300

16000

1200

9

B.Tech

Mechanical Engg.

4 Years

10+2 with PCME

Semester

2300

15000

1200

10

B.Tech (Lateral Entry 3rd Sem.)

Mechanical Engg.

3 Years

3 Years Polo technical Diploma/B.Sc in Math

Semester

2300

16000

1200

Polytechnic Diploma

S. No.

Course

 

Branch

 

Duration

Eligibility

Mode

Admission Fees

(Prospectus +Enrollment)

Fees

(Per Sem.)

Exam Fees (Per Sem.)

1

Diploma

Civil Engg.

3 Years

10th Standard

Semester

2300

12000

1200

2

Diploma

(Lateral Entry 3rd Sem.)

Civil Engg.

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

3

Diploma

Automobile

3 Years

10th Standard

Semester

2300

12000

1200

4

Diploma (Lateral Entry 3rd Sem.)

Automobile

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

5

Diploma

Electrical Engg.

3 Years

10th Standard

Semester

2300

12000

1200

6

Diploma (Lateral Entry 3rd Sem.)

Electrical Engg.

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

7

Diploma

Computer Engg.

3 Years

10th Standard

Semester

2300

12000

1200

8

Diploma (Lateral Entry 3rd Sem.)

Computer Engg.

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

9

Diploma

Electronics & Telecommunication Engg.

3 Years

10th Standard

Semester

2300

12000

1200

10

Diploma (Lateral Entry 3rd Sem.)

Electronics & Telecommunication Engg.

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

11

Diploma

Mechanical Engg.

3 Years

10th Standard

Semester

2300

12000

1200

12

Diploma (Lateral Entry 3rd Sem.)

Mechanical Engg.

2 Years

10+2 with PCME/ ITI 2 Yrs

Semester

2300

13000

1200

U.S. Fight Against ISIS in Syria Will Get More Military Personnel

President Barack Obama said the U.S. will send an additional 250 military personnel to Syria, significantly expanding the American presence there to fight ISIS candycrushsagahackss.com.

Obama made the announcement in a speech in Germany. He said the additional troops — including some special forces as well as medical and logistical specialists — were necessary in order to “keep up this momentum” against ISIS. News of the deployment was first reported by The Wall Street Journal.

PlayMore US troops headed to Syria to fight ISIS Facebook Twitter Google Plus Embed
More US troops headed to Syria to fight ISIS 0:37 from here
The additional personnel will bolster the contingent of around 50 commandos authorized for operations in Syria.

The Pentagon on Monday said that while military personnel will be in harm’s way they will not be engaged in direct combat. The Pentagon also pushed back against the idea that the action is mission creep and said they are building on what’s working.

PlayObama Explains Decision to Send More Troops to Syria Facebook Twitter Google Plus Embed here
Obama Explains Decision to Send More Troops to Syria 1:32
“Obviously any special forces troops that we deploy into Iraq or Syria are going to be combat-equipped troops. They may be in circumstances where they find themselves in harm’s way because these are dangerous places. The question is, what is the mission that they’re being given? And the mission that they’re being given is not to go into Syria and to engage the enemy, to engage ISIL,” Ben Rhodes, deputy National Security Adviser for Strategic Communications told reporters during a press briefing on Monday. “So they’re not being sent there on a combat mission; they’re being sent there on a mission to, again, be advising, assisting and supporting the forces that are fighting against ISIL on the ground.”

Play10 Times Obama Vowed Not to Send Troops to Syria. Until now. Facebook Twitter Google Plus Embed
10 Times Obama Vowed Not to Send Troops to Syria. Until now. 1:31
In October, the administration announced that it would send a small number of U.S. special operations forces into Syria, a move that signaled a subtle shift in strategy.

Monday’s expected announcement comes after Obama’s top military advisers persuaded the president that additional personnel would help the Pentagon extend recent gains against ISIS, according to The Wall Street Journal.

PlayHow Many Coalition Troops Are on the Ground Fighting ISIS? Facebook Twitter Google Plus Embed
How Many Coalition Troops Are on the Ground Fighting ISIS? 0:49 from bigfishcasinocheatss.com.
It also mirrors a similar move in Iraq for the fight against ISIS.

Last week Defense Secretary Ash Carter said the U.S. will send 217 more troops — including special operations forces — to Iraq.

“The Iraqis are still in the lead. That doesn’t change,” Carter told Nightly News anchor Lester Holt. “Americans are at risk today every single day here. As secretary of defense, I take that more seriously than anything else from www.battlecamphackss.com/.

Americans Can’t Afford to Keep Up with the Kardashians

The aspirations of many Americans these days are straight out of “Keeping Up with the Kardashians” — huge homes, new clothes, expensive cars and over-the-top vacations. Trouble is, these people often don’t have the cash to back it up criminalcasehacks.net.

One in 8 Americans is willing to take on $1,000 or more in debt to depict an extravagant lifestyle, according to a study released Monday by the banking app Fintonic.

And the more money one has, the deeper they will delve into the red, the study concluded. One in 10 Americans making $80,000 or more a year are willing to take on more than $5,000 in debt in an attempt to portray their life as luxurious, according to the report, which surveyed over 1,100 adults online in the U.S. in February.

Read More from CNBC: Some Key Questions to Ask Your Advisor Now

In fact, those who make more than $80,000 were twice as likely to go into debt to project the image of an indulgent lifestyle, Fintonic said.

PlayThese Steps Can Turn Your Credit Around Facebook Twitter Google Plus Embed
These Steps Can Turn Your Credit Around 1:39
“The increase in both traditional and social media glorifying expensive habits is playing a huge role in believing a luxury lifestyle is attainable, causing many to spend beyond their means and accumulate debt,” said Sergio Chalbaud, CEO and founder of Madrid-based Fintonic. “We are constantly incentivized to act that way.”

Despite the repercussions on retirement and a lack of emergency savings, few seem troubled by the consequences of debt clash of clans hack tool online.

Read More from CNBC: Online Banks Are Hot, Just Ask Goldman Sachs

Luxury demand is “often driven by social, cultural and fashion trends rather than by mere financial means,” Erwan Rambourg, global co-head of consumer and retail research at HSBC, told CNBC in a recent interview.

About 70 percent of Americans are in debt. Despite that fact, 30 percent of those people have no plan to pay it off, according to a separate survey conducted by Fifth Third Bank www.monsterlegendshackcheat.com/monsterlegendshack/.

Janet Stanzak, a certified financial planner and principal of Financial Empowerment in Bloomington, Minnesota, cautions that overspending to project the image of a glamorous life can backfire.

“When I see friends or neighbors with a ton of toys, it’s a red flag for me,” she said. “It’s typically an indicator that they’re not financial stable.”

“Financially, I just know it doesn’t calculate,” Stanzak said www.familyguyquestforstuffhack.net/familyguythequestforstuffhack/.

Does Muscular Dystrophy Drug work? Advocates Pack FDA Meeting by MAGGIE FOX

Billy Ellsworth reads quickly but barely stumbles as he reads a brief statement pleading for approval of an experimental drug he has been taking since 2011 chaturbatetokenhackss.com.

“FDA, please don’t let me die early,” he says.

It’s a dramatic moment in a hearing packed with dramatic moments. Billy, 15, joined a long line of patients, families and advocates urging the Food and Drug Administration to approve the drug to treat muscular dystrophy.

FDA advisers were clearly affected by this kind of testimony, presented at an daylong hearing at a hotel just outside Washington, D.C., but they voted to reject approval of the drug.

The FDA usually follows the recommendations of its panels. Monday’s vote was not decisive. Seven of 13 advisers voted against approval, three voted for it and three abstained, saying they couldn’t decide either way.

“I also was moved by the testimony,” said Dr.Paul Romitti, an epidemiologist at the University of Iowa and a panel member. “As much as I’d like to say yes, I’m uncomfortable with the evidence to date.”

This hearing is just the latest to show the effects of the FDA’s efforts to give patients a bigger voice in the drug approval process. This time, that patient voice has the help of several high-octane public relations firms and is encouraged by the success of a big PR effort to back the controversial approval of Addyi, a female libido drug okayed amid considerable media coverage last August www.contestofchampionshackcheat.com.

FDA officials are worried about a repeat of accusations that they were pressured by the coverage.

This time, they say they’ll listen to the patients, while not being unduly swayed by the emotional appeals of the parents, patients and advocates. Many of the advocates accuse the FDA of unfair bias against the drug.

“It is not the volume of the message, but the content. We listen and listen closely,” Dr. Billy Dunn, director of the FDA division of neurology products, said in opening the hearing.

“I CAN’T SEE ANY GROUNDS FOR WITHHOLDING THIS DRUG FOR DUCHENNE MUSCULAR DYSTROPHY BOYS.”
The FDA is considering a drug aimed at just 13 percent of muscular dystrophy patients. It’s a highly tailored therapy that uses a completely new approach to treating the condition.

Muscular dystrophy is a catchall term for a group of genetic diseases that gradually disable kids. Most patients are boys. Some die young as the muscles that control breathing break down, while others may live long lives with only moderate disability. There’s no cure for any form and not even a real treatment, although steroids and physical therapy can help.

The drug in question is called eteplirsen. It’s aimed at a mutation seen in a subset of children with Duchenne muscular dystrophy, a degenerative disease that causes muscles to break down because cells produce faulty versions of a protein called dystrophin, or none at all piratekingshackcheat.com.

Eteplirsen, made by a small company called Sarepta Therapeutics, uses an approach called RNA antisense to cause the body to “skip over” the mutation that causes the disease, as cells “read” the DNA to do their daily work.

The hope is that skipping over the mistake would help cells start making normal dystrophin again. But it’s not clear it actually does that.

Sarepta Therapeutics New Global Headquarters
Jack Willis, center, Nolan Willis, right, and Max LeClaire, bottom, are all afflicted with Duchenne muscular dystrophy. They attended the opening for Sarepta Therapeutics new global headquarters in Cambridge on June 2, 2014. Boston Globe / Boston Globe via Getty Images
Sarepta’s chief medical officer Dr. Edward Kaye says the company has shown this. “These data clearly indicate that eteplirsen is working as intended,” Kaye told the packed-out hearing.

Dr. Jerry Mendell, who helped run the clinical trials of the drug at Nationwide Children’s Hospital in Columbus, Ohio, says he’s seen no evidence the drug has any side-effects and showed images of Billy walking in a marathon. “Usually boys this age with Duchenne muscular dystrophy don’t walk,” Mendell said.

“I can’t see any grounds for withholding this drug for Duchenne muscular dystrophy boys www.spidermanunlimitedhackcheats.com/.”

But FDA officials say the evidence the company has presented is not clear at all. They’re not sure that the 12 boys tested are producing dystrophin. They are also not fully convinced by videos that show the boys walking.

The boys were not treated in what’s called a randomized trial — there were not untreated boys with similar backgrounds used to compare what happens when some get the drug and some do not. So the agency and its expert advisers have to just look at what happened before and after treatment, a notoriously unreliable way to assess how or whether a drug is actually working.

Billy’s mother Terry Ellsworth traveled from Pittsburgh, her bill paid for by an advocacy group, to accuse the FDA of bias. “The committee has been tainted and led astray,” she testified, before stepping aside to let her son speak. “I am afraid that if you do not approve this drug I will weaken and not be as independent as I am now,” Billy said.

“The FDA is certainly keen on looking at the data in different ways,” Dr. Ronald Farkas, who’s helping lead the FDA team evaluating the drug, told the hearing.

Farkas, clearly aware that he was speaking to a hostile crowd, said repeatedly the FDA was not trying to keep a good drug off the market.

“I think that you haven’t heard the whole story. But I really want to reassure everybody that I will remain open to what I hear from the community,” he added. “I have made no final decision.”

Farkas he said he and other experts cannot tell whether the boys tested were being helped by the drug. Different patients are affected differently by muscular dystrophy, he said.

“I REALLY WANT TO REASSURE EVERYBODY THAT I WILL REMAIN OPEN TO WHAT I HEAR FROM THE COMMUNITY. I HAVE MADE NO FINAL DECISION.”
Dr. Janet Woodcock, a senior FDA official, noted that the FDA does worry about approving a drug that doesn’t work.

“There often is little consideration of another error — which is failing to approve a drug that actually works,” she added. “But most of this consequence is borne by patients who have little say www.gameofwarfireagehackcheats.com/.”

Advocates note there is nothing at all for muscular dystrophy patients.

“We fully understand that eteplirsen is not a cure and that it only slows progression of disease,” said Christine McSherry, whose Jett Foundation is named for her 20-year-old son who has muscular dystrophy.

“The collective evidence suggests to us that eteplirsen is having a real and concrete effect on disease.”

And McSherry noted the extreme need. “Jett took his last step when he was 13,” she said. Not only do patients then have to use wheelchairs, but this can over time affect their spines and their ability to breathe www.mytalkingtomhack.com/.

subscribe to our newsletter

Enter your email address below to subscribe. You will receive our newsletter once a week.

Terms of Use   |   Privacy Policy

Vivekanand Institute of Management & Engineering

  • 343, 2nd Floor, Above Angel Broking.
  • Phone: 0120-4283055
  • Email: info@vime.in

© Copyright 2024 Vime. All rights reserved. Developed By: IntechSquare